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Objective:  International studies on childhood type 1 diabetes (T1D) have focused on whole-
country mean HbA1c levels thereby concealing potential variations within countries. We aimed 
to explore variation in HbA1c across and within eight high-income countries to best inform 
international benchmarking and policy recommendations.   
Research Design and Methods: Data were collected between 2013/14 from 64,666 children 
with T1D <18 years across 528 centres in Germany, Austria, England, Wales, USA, Sweden, 
Denmark, and Norway. We used fixed and random effect models adjusted for age, gender, 
diabetes duration, and minority status to describe differences between centre means and 
calculate the proportion of total variation in HbA1c that is attributable to between-centre 
differences (Intra-Class Correlation-ICC). We also explored the association between within-
centre variation and children’s glycaemic control.  
Results: Sweden had the lowest mean HbA1c (59mmol/mol; 7.6%) and together with Norway 
and Denmark showed the lowest between-centre variations (ICC≤4%). Germany and Austria 
had the next lowest mean HbA1c (61-62mmol/mol;7.7-7.8%) but showed the largest centre 
variations (ICC~15%). Centres in England, Wales, and the USA showed low-to-moderate 
variation around high mean values. In pooled analysis, differences between counties remained 
significant after adjustment for children characteristics and centre effects (p-value<0.001). 
Across all countries, children attending centres with more variable glycaemic results had 
higher HbA1c (5.6 mmol/mol [0.5%] per 5 mmol/mol [0.5 %] increase in centre HbA1c-
standard deviation).  
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Conclusion: At similar average levels of HbA1c, countries display different levels of centre 
variation. Distribution of glycaemic achievement within countries should be considered in 






For children with type 1 Diabetes (T1D), achievement of optimal metabolic control, as 
measured by levels of glycated haemoglobin (HbA1c), is important in reducing the risk of 
vascular complications in later life (1). Guidelines from national and international 
organisations set specific standards of care and recommend a target HbA1c of less than 48-58 
mmol/mol (6.5-7.5%) for most children with T1D (2-5) . Despite the evidential and clinical 
consensus, many children with T1D in developed Western nations fail to achieve target 
glycaemic control. Management of T1D requires ongoing patient education, access to 
appropriate treatment, and coordinated guidance from multidisciplinary teams thus providing 
important insights into various elements of national health systems and their communication 
(6). Within-country studies have reported substantial differences in glycaemic control across 
paediatric diabetes centres (7-9). Although some of these variations could be related to 
differences in patient case-mix or preferences, some others may reflect differences in quality 
of, or access to, diabetes care. These unwarranted variations raise concerns about the equity 
of health care systems.  
To date, analyses of between-centre variation in childhood T1D outcomes have been typically 
conducted within individual countries, with existing international studies focusing on crude 
centre comparisons (10) or on comparisons between selected centres that are not representative 
of their respective countries (11-13). Although this approach has provided national 
opportunities for improvement, it has been less informative about systems’ performance 
relative to other countries. At the same time, international comparisons on T1D have 
predominantly focused on whole country mean or median HbA1c levels (14; 15). Such 
comparisons are inherently limited, as they may conceal within-country variations. This 
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represents a missed opportunity for cross-country learning. Each child with T1D should 
receive equal quality of care, regardless of the child’s country of residence, or the centre 
coordinating the child’s diabetes care within a specific country. Therefore, exactly how 
between-centre variation in glycaemic control differs across countries remains an important 
unanswered question. Similarly, variation within each centre and country is of interest, as 
consistently good results are desired. 
In the current study, we aimed to describe the extent of variation in glycaemic control across 
and within eight high income countries, seven in Western Europe and the USA. Our specific 
objectives were: to describe variation in HbA1c across countries and between centres within 
countries; to explore what proportion of the total variation in children’s glycaemic control is 
attributable to differences between centres in each country; to examine cross-country 
differences in the association between within centre variation and children’s metabolic 
control; and finally to examine whether differences in country mean HbA1c persist after 
adjusting for patient characteristics and centre effects.  
Methods   
Study design and participants 
Anonymised data from six large registries/audits on children with T1D were used, representing 
eight countries: Germany and Austria from the Prospective Diabetes Follow-up Registry 
(DPV) (16), England and Wales from the National Paediatric Diabetes Audit (NPDA) (17), 
USA from the T1D Exchange (T1DX) (18), Sweden from the Swedish Pediatric Diabetes 
Quality Registry (SWEDIABKIDS) (8), Denmark from the Danish National Diabetes Registry 
(DanDiabKids) (19), and Norway from the Norwegian Childhood Diabetes Registry (NCDR) 
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(20). All data sources were population-based registries or audits covering >80% of the national 
population of children with T1D, except for T1DX which was a clinic-based registry (see 
Table 1). Participants were included in the analysis if they were diagnosed with T1D for at 
least 3 months (since levels of HbA1c during the first 3 months post diagnosis are not reflective 
of ongoing diabetes care delivered by the centre), were aged <18 years, and they had at least 
one HbA1c measurement in 2013 (except for England and Wales where data were collected 
between April 2013 and March 2014). We excluded children with missing information on risk 
adjustors and children who changed clinic during the study period. Finally, we excluded clinics 
with available data for less than 10 children for confidentiality reasons. The final sample 
consisted of 64,666 children with T1D across 528 centres (see supplemental Figure S1). The 
study was approved by the individual registry/audits in each country with ethical approval to 
collect patient data.  
Outcome and risk adjustment 
Glycaemic control was assessed by levels of HbA1c. All registries reported HbA1c in 
mmol/mol in accordance with the International Federation of Clinical Chemistry (IFCC) (21). 
Corresponding NGSP units (%) are given in parenthesis. The median HbA1c value over the study 
period was used for each child; however, two countries only provided a single HbA1c 
measurement for each child (first registered value during 2013 in Norway and value closest to 
child’s birthday in Denmark). 
To ensure a fair comparison between centres we adjusted our analyses for four clinically 
important glycaemic determinants that are outside the control of the clinic; these included 
children’s gender, age (<6 years, 6 to <12 years, and 12 to 18 years), duration of diabetes (<2 
years, 2 to <5 years, and ≥ 5 years) and minority status (yes/no). We also allowed for the 
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association between diabetes duration and HbA1c to vary across age categories by including 
age-duration interaction terms. Minority status was defined using patient/parent’s country of 
birth or patient’s ethnicity status (Table 1). Given the differences in the definition of minority 
status between countries, we repeated our analyses after excluding minority status from risk 
adjusted models and observed any differences in centre variations across countries.  
Statistical analysis 
We first used country-specific, risk-adjusted fixed effect models to obtain estimates of mean 
HbA1c levels for each centre following established methodology (22). Estimates derived from 
these models are akin to comparing centres in each country as if they had the same composition 
of children in terms of age, gender, diabetes duration and minority status. We visualised 
variation between adjusted centre means in each country by constructing boxplots with the 
distance between the top and the bottom of the box representing the middle 50% of centres. 
Given the traditional emphasis of international comparisons on mean HbA1c values, we 
presented centre variations together with crude national mean values. To convey the absolute 
difference in glycaemic control between centres with relatively low versus high HbA1c value 
within each country, we calculated the difference in adjusted glycaemic levels between centres 
in the highest and lowest decile of each country’s distribution (i.e. middle 80% range). 
In addition to describing differences between centre means, we further used risk-adjusted 
models with a random effect for centre to calculate the proportion of total variation in 
glycaemic control attributable to differences between centres in each country (Intra-Class 
Correlation -ICC=  
𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑐𝑒𝑛𝑡𝑟𝑒 𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒
𝑡𝑜𝑡𝑎𝑙 𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒
)(23). ICC provides important information about 
how glycaemic control is distributed across centres within a country and helps determine the 
national scope for improvement that might be possible by reducing variation between centres 
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(23).  For example, large values of ICC suggest that children’s glycaemic outcomes are 
heterogeneously distributed across centres and interventions targeting low performing centres 
are likely to capture most of the poorly controlled children in the country. By contrast, a low 
ICC indicates that glycaemic control is homogeneously achieved across centres and 
geographically targeted interventions aiming to only reduce variation between centres may 
have a limited influence on nationwide improvements. Therefore, this analysis could help a 
national health system or registry to target resources to most efficiently improve outcomes.  
Additionally, we measured variability in glycaemic results within each centre by calculating 
the standard deviation of HbA1c values of all children attending a specific centre (HbA1c-SD). 
The HbA1c-SD reflects the average deviation of a child from its centre mean and provides an 
indicator of how consistent the glycaemic performance of the centre is. We extended the above 
country-specific, risk-adjusted models with a random effect for centre by introducing HbA1c-
SD as a centre-level variable. Since centre variability may be influenced by the number of 
children attending the centre, we also adjusted all models for centre volume. We extracted 
country-specific HbA1c-SD regression coefficients and pooled them by random effects meta-
analysis.  
Finally, we conducted a pooled analysis of glycaemic data including children from all 
countries to explore whether differences in mean HbA1c between countries persist after 
removing centre effects and differences in the risk profile of children across countries. In the 
pooled dataset, we ran a risk-adjusted model with a random effect for centre and introduced 
country as a fixed effect. Estimates of country means from the above model are similar to 
comparing countries as if they had the same composition of children and the same centre 
characteristics. Hence, any differences can be fairly attributed to countries.    
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Parameters in random effects models were estimated using the maximum likelihood method. 
Model fit was examined by using the likelihood ratio test (LRT). Distribution of individual 
and centre-level residuals were checked in all models and showed approximate normality. P-
values <.05 were considered statistically significant. All analyses were performed using SAS 
version 9.4 (SAS Institute, Cary, NC) and Stata version 13 (StataCorp; College Station, TX).  
Results  
Characteristics of children in each country are presented in Table 1. Children had a similar 
gender and age profile across all eight countries. Mean duration of diabetes was lowest in 
Germany and Austria (4.6 years) and highest in the USA (5.7 years). Minority status varied 
considerably from 5% in Wales to >26% in Austria and England. Achievement of the 
International Society of Pediatric and Adolescent Diabetes (ISPAD) HbA1c target of <58 
mmol/mol (7.5%) ranged from 17% in Wales to 49% in Sweden. Characteristics of diabetes 
centres are presented in Supplemental Table S1.  
Figure 1A shows how adjusted centre mean HbA1c levels vary around crude national mean 
values in each of the eight countries. Table 2 also shows the difference in mean HbA1c levels 
achieved between centres in the highest and lowest decile of their country’s distribution. 
National mean levels of HbA1c showed a 1.2-fold variation across countries from 59 mmol/mol 
(7.6%) in Sweden to 72 mmol/mol (8.8%) in Wales. Sweden and Norway showed the lowest 
variation between centres; in both countries, the difference in risk-adjusted mean HbA1c 
between centres in the lowest and highest decile was 6-7 mmol/mol (0.6%). Germany and 
Austria had the second and third lowest mean HbA1c values. However, they both showed the 
largest between-centre variations with centres in the highest decile having higher mean HbA1c 
levels by more than 14 mmol/mol (1.3%) as compared to centres in the lowest decile. Figure 
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1B shows the distribution of adjusted centre means by registry/audit against the ISPAD 
glycaemic target. 
Table 2 shows the share of the total variation in HbA1c that is attributable to differences 
between centres in each country after controlling for children characteristics. Adjusted ICCs 
in most countries were low, indicating that centres accounted for only a small proportion of 
the total variation in children’s glycaemic control. However, adjusted ICCs varied 
considerably across countries, ranging from 4% or less in Nordic countries to around 15% in 
Germany and Austria. Exclusion of minority status from risk adjustment only marginally 
affected centre differences and ICCs except for the USA, where exclusion of minority status 
resulted in a substantial reduction in ICC from 7.9% to 6.6%.   
We also looked at the association between centre HbA1c-SD and children’s glycaemic 
outcomes varies across the eight countries. Across all countries, children who attended centres 
with larger variation in their glycaemic performance (i.e. higher centre HbA1c-SD) had, on 
average, higher HbA1c. Overall, there was a deterioration in glycaemic control by 5.6 
mmol/mol; (0.5%) per 5 mmol/mol (0.5%) increase in centre HbA1c-SD, however this varied 
from 2.8 mmol/mol (0.3%) in Norway to 7.2 mmol/mol (0.7%) in Austria (see supplemental 
figure S2).  
In the pooled analysis, differences between country mean HbA1c values were slightly 
attenuated after controlling for cross-country differences in patient characteristics and centre 
effects (see Figure 2). However, addition of country in the risk-adjusted random effects model 
showed that the country where a child received care was a significant determinant of 




We described variation in glycaemic control between and within eight high-income countries 
using data from multicentre registries/audits for children with T1D. We found that crude mean 
HbA1c varied by 1.2-fold across countries. However, in some countries variation between 
centres was even larger than these cross-country differences. We also calculated the proportion 
of total variation in HbA1c which is attributable to differences between centres and we found 
this to vary from 4% or less in Nordic countries to around 15% in Germany and Austria. 
Across all countries, children who attended centres with larger variability in their glycaemic 
performance had poorer glycaemic control. Finally, differences between country mean HbA1c 
levels remained significant even after controlling for differences in patient and centre 
characteristics.  
We found that Sweden had the lowest mean HbA1c and together with the other Nordic 
countries demonstrated small centre variations indicating that low levels of glycaemic control 
are homogeneously achieved by most children regardless of the clinic they attend. In Nordic 
countries, the establishment of collaboration between quality registries has been a major effort 
in promoting performance improvement in paediatric diabetes (10). Sweden has been 
particularly successful in establishing a nationwide program of continuous quality 
improvement in paediatric diabetes care which includes transparent public reporting of centre 
performance, systematic monitoring of variations, use of performance data as a clinical tool 
for professional development, and active participation of centres in Quality Improvement 
“Collaboratives”. This system-wide approach probably accounts, at least in part, for the 
improved glycaemic outcomes in Sweden (24) . 
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Another important finding was that a lower national average glycaemic control does not 
necessarily reflect homogenous distribution within a country. For example, large centre 
variations were observed in Germany and Austria, countries with average HbA1c levels 
comparable to those of Sweden. In those countries, around 15% of the total variation in HbA1c 
was located at the level of the centre which suggests that targeted interventions aiming to 
reduce centre variability could have an appreciable impact on glycaemic outcomes. Such large 
variations may be partly related to the structure of diabetes care. Unlike the UK and Nordic 
countries, where diabetes care is predominantly provided by hospital-based clinics normally 
treating children in their catchment areas, in Germany and Austria, patients are free to choose 
their providers by a blend of hospital-based and private practices. This open competition might 
result in centres exhibiting variations in their discretionary policies. However, the magnitude 
of centre variation is unlikely to be solely explained by uncaptured differences in patient mix 
or preferences.  
In Germany and Austria, nationwide benchmarking has been provided to participating 
pediatric diabetes teams since 1995 in anonymized form. Analyses reporting quality indicators 
with each center openly identified are available since 2000 for regional quality circles and 
since 2016 for all pediatric diabetes institutions in both countries. However, de-anonymized 
reports are not openly available to the public (16). Benchmarking schemes were absent in the 
USA registry, where moderate centre variations were observed. Public reporting of 
performance indicators in paediatric diabetes care has long been used as a core component of 
the accountability for quality improvement in Nordic countries and since 2012 in England and 
Wales. Evidence from other medical specialties shows that public disclosure of provider 
performance measures is linked to improved performance and has limited impact on patient 
movements (25). However, a climate of mutual trust needs to be created between clinicians 
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and other stakeholders when implementing such policies to avoid defensive behaviors 
potentially leading to discontinuing of information sharing.  
Policies aiming to narrow centre variation in paediatric diabetes care should be prioritised, yet 
such policies might not be sufficient to address cases where all centres in a nation are 
performing sub-optimally. This might be the case in countries with high average HbA1c levels 
and low-to-moderate ICCs such as England, Wales, and the USA. Some of the best clinics in 
those countries performed poorly when compared even with Swedish centres at the higher end 
of the distribution. This implies that quality improvement in those countries might best be 
achieved not only by targeting poor performers, but also by “shifting the curve” of overall 
paediatric diabetes practice towards higher quality levels. The recent changes towards tighter 
HbA1c targets for all children of <48 mmol/mol (6.5%) in the UK (2) and <58 mmol/mol 
(7.5%) in the USA (3) could help towards achieving this goal. International experience has 
also shown that patient-centered policies might be effective in stimulating whole system 
improvements (26). For example, the introduction of patient-reported experience measures 
(PREM) for paediatric diabetes care in England and Wales in 2013 is considered an important 
step in informing local decision making (27). 
In all countries, children who attended centres with more variable glycaemic results had, on 
average, higher HbA1c. This finding may reflect a range of factors related to goal setting, team 
cohesiveness and organizational culture. Previous reports from the Hvidore study group 
demonstrated improved glycaemic performance in centres where the team set consistent 
HbA1c targets (28). Achievement of higher consistency within a centre also requires focusing 
attention on management of challenging populations of children who are more likely to exhibit 
greater variability in their metabolic control (e.g. adolescents). Taken together, our findings 
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suggest that, in addition to helping a higher percentage of their patients achieve target glycemic 
control, centres should also aim for lower variability in their glycaemic performance.   
We also found significant differences between countries’ glycaemic levels over and above 
children characteristics and centre differences. Several aspects of paediatric diabetes care 
could contribute to these differences, including use of insulin pumps, patient education, 
lifestyle factors, training of healthcare professionals, impact of low socioeconomic status, and 
reimbursement schemes. However, the link with glycaemic outcomes is not straightforward. 
For example, a previous study showed that although pump use in children with T1D was much 
lower in England and Wales (14%) as compared to Germany, Austria (41%), and the USA 
(47%), country differences in glycaemic control could not be adequately explained by 
differences in insulin delivery method (29). The results may have also been influenced by 
national HbA1c target levels. At the time of the study these were equal to or below 58 
mmol/mol (7.5%) in Germany, Norway, England, and Wales; 52 mmol/mol (6.9%) in Sweden, 
53 mmol/mol (7.0%) in Austria; 55 mmol/mol (7.2%) in Denmark; 69 mmol/mol (8.5%) for 
children under 6 years of age, 64 mmol/mol (8.0%) for children 6-12 years old, and 58 
mmol/mol (7.5%) for children ≥13 years of age in the USA. However, in our figures we 
presented the ISPAD HbA1c target of <58 mmol/mol (7.5%) which has been adopted by most 
countries in order to put country data in context by providing an internationally agreed target. 
Our study should be interpreted within the context of its limitations. First, risk adjustment was 
restricted to availability of comparable data. It is possible that unaccounted factors such as co-
morbidities and socioeconomic status might systematically vary between centres and therefore 
explain some of the observed variations. Second, in line with previous studies (14; 29), we 
used the median HbA1c measurement for each child to avoid the effects that outliers can have 
on the mean. However, this approach may not accurately represent glycaemic exposure over 
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the observation period. Third, although all registries reported IFCC-aligned HbA1c values, it 
is likely that differences in laboratory methods across countries might have contributed to the 
observed variations. Fourth, we excluded centres with less than 10 children which might have 
underestimated centre variations in countries with many small practices (i.e. Germany). Fifth, 
differences in the definition of minority status across countries might have affected our 
comparisons. However, exclusion of minority status from risk adjustment only minimally 
affected our results in most countries. In the USA, larger centre differences were masked by 
failing to adjust for minority status; such a result could occur, for example, when poorly 
performing centres have fewer minority children who tend to have poorer outcomes than non-
Hispanic whites (30). Moreover, data from the USA were based on a selective group of 
diabetes clinics and might not be directly comparable with that of the European population-
based registries. Finally, our analysis was a snapshot comparison of glycaemic levels; a more 
dynamic comparison would be needed to address the link between quality improvement 
initiatives and glycaemic performance. 
In summary, our findings from this large international study showed considerable differences 
in mean HbA1c between and within countries. At similar average levels of glycaemic control, 
countries displayed very different levels of centre variation. This suggests that whole-country 
mean HbA1c levels are an inadequate summary of a country’s glycaemic performance. 
Distribution of glycaemic achievement across centres within countries should be considered, 
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Figure legends  
 
Figure 1. Between-centre variation in HbA1c across countries. Centre means derived 
from linear fixed effect regression models adjusted for patient characteristics (gender, 
age, duration of diabetes, and minority status).  
(A) Boxplots showing centre variation in adjusted mean HbA1c across eight countries. The 
shaded box represents the interquartile range (IQR) capturing the middle 50% of the centres. 
Whiskers extend to include centres within 1.5 times the IQR beyond the upper and lower 
quartile; dots outside the whiskers represent outlying centres; crude national average HbA1c 
values are represented by diamonds.   
(B) Kernel-smoothed distribution of adjusted centre HbA1c means by registry/audit. The 
dashed vertical line represents the International Society of Pediatric and Adolescent Diabetes 
(ISPAD) glycaemic target recommended for children with diabetes.  
 
 
Figure 2. Country mean HbA1c before and after adjustment for cross-country 
differences in children characteristics (age, gender, diabetes duration, and minority 
status) and centre effects. Estimates of adjusted country means derived from a two-level 




1. Nathan DM, Bayless M, Cleary P, Genuth S, Gubitosi-Klug R, Lachin JM, Lorenzi G, 
Zinman B: Diabetes control and complications trial/epidemiology of diabetes interventions and 
complications study at 30 years: advances and contributions. Diabetes 2013;62:3976-3986 
2. NICE clinical quideline: Diabetes (type 1 and type 2) in children and young people: 
diagnosis and management [article online], 2015. Available from 
https://www.nice.org.uk/guidance/ng18/resources/diabetes-type-1-and-type-2-in-children-
and-young-people-diagnosis-and-management-1837278149317.  
3. Chiang JL, Kirkman MS, Laffel LM, Peters AL, Type 1 Diabetes Sourcebook A: Type 1 
diabetes through the life span: a position statement of the American Diabetes Association. 
Diabetes Care 2014;37:2034-2054 
4. Hofer S, Bauer M, Lanzersdorfer R, Walser I: Diabetes mellitus bei Kindern und 
Jugendlichen. Pädiatrie & Pädologie 2010;Suppl 3/2010  
5. Rewers MJ, Pillay K, de Beaufort C, Craig ME, Hanas R, Acerini CL, Maahs DM, 
International Society for P, Adolescent D: ISPAD Clinical Practice Consensus Guidelines 
2014. Assessment and monitoring of glycemic control in children and adolescents with 
diabetes. Pediatr Diabetes 2014;15 Suppl 20:102-114 
6. Nolte E, Bain C, McKee M: Diabetes as a tracer condition in international benchmarking of 
health systems. Diabetes Care 2006;29:1007-1011 
7. Gerstl EM, Rabl W, Rosenbauer J, Grobe H, Hofer SE, Krause U, Holl RW: Metabolic 
control as reflected by HbA1c in children, adolescents and young adults with type-1 diabetes 
mellitus: combined longitudinal analysis including 27,035 patients from 207 centers in 
Germany and Austria during the last decade. Eur J Pediatr 2008;167:447-453 
8. Hanberger L, Samuelsson U, Lindblad B, Ludvigsson J, Swedish Childhood Diabetes 
Registry S: A1C in children and adolescents with diabetes in relation to certain clinical 
parameters: the Swedish Childhood Diabetes Registry SWEDIABKIDS. Diabetes Care 
2008;31:927-929 
9. Scottish Study Group for the Care of the Young D: Factors influencing glycemic control in 
young people with type 1 diabetes in Scotland: a population-based study (DIABAUD2). 
Diabetes Care 2001;24:239-244 
10. Hanberger L, Birkebaek N, Bjarnason R, Drivvoll AK, Johansen A, Skrivarhaug T, 
Thorsson AV, Samuelsson U: Childhood diabetes in the Nordic countries: a comparison of 
quality registries. J Diabetes Sci Technol 2014;8:738-744 
11. Danne T, Mortensen HB, Hougaard P, Lynggaard H, Aanstoot HJ, Chiarelli F, Daneman 
D, Dorchy H, Garandeau P, Greene SA, Hoey H, Holl RW, Kaprio EA, Kocova M, Martul P, 
Matsuura N, Robertson KJ, Schoenle EJ, Sovik O, Swift PG, Tsou RM, Vanelli M, Aman J, 
Hvidore Study Group on Childhood D: Persistent differences among centers over 3 years in 
glycemic control and hypoglycemia in a study of 3,805 children and adolescents with type 1 
diabetes from the Hvidore Study Group. Diabetes Care 2001;24:1342-1347 
12. de Beaufort CE, Lange K, Swift PG, Aman J, Cameron F, Castano L, Dorchy H, Fisher 
LK, Hoey H, Kaprio E, Kocova M, Neu A, Njolstad PR, Phillip M, Schoenle E, Robert JJ, 
Urukami T, Vanelli M, Danne T, Barrett T, Chiarelli F, Aanstoot HJ, Mortensen HB, Hvidoere 
Study G: Metabolic outcomes in young children with type 1 diabetes differ between treatment 
centers: the Hvidoere Study in Young Children 2009. Pediatric Diabetes 2013;14:422-428 
13. de Beaufort CE, Swift PG, Skinner CT, Aanstoot HJ, Aman J, Cameron F, Martul P, 
Chiarelli F, Daneman D, Danne T, Dorchy H, Hoey H, Kaprio EA, Kaufman F, Kocova M, 
21 
 
Mortensen HB, Njolstad PR, Phillip M, Robertson KJ, Schoenle EJ, Urakami T, Vanelli M, 
Hvidoere Study Group on Childhood D: Continuing stability of center differences in pediatric 
diabetes care: do advances in diabetes treatment improve outcome? The Hvidoere Study Group 
on Childhood Diabetes. Diabetes Care 2007;30:2245-2250 
14. Maahs DM, Hermann JM, DuBose SN, Miller KM, Heidtmann B, DiMeglio LA, Rami-
Merhar B, Beck RW, Schober E, Tamborlane WV, Kapellen TM, Holl RW, Initiative DPV, 
Network TDEC: Contrasting the clinical care and outcomes of 2,622 children with type 1 
diabetes less than 6 years of age in the United States T1D Exchange and German/Austrian DPV 
registries. Diabetologia 2014;57:1578-1585 
15. McKnight JA, Wild SH, Lamb MJ, Cooper MN, Jones TW, Davis EA, Hofer S, Fritsch M, 
Schober E, Svensson J, Almdal T, Young R, Warner JT, Delemer B, Souchon PF, Holl RW, 
Karges W, Kieninger DM, Tigas S, Bargiota A, Sampanis C, Cherubini V, Gesuita R, Strele I, 
Pildava S, Coppell KJ, Magee G, Cooper JG, Dinneen SF, Eeg-Olofsson K, Svensson AM, 
Gudbjornsdottir S, Veeze H, Aanstoot HJ, Khalangot M, Tamborlane WV, Miller KM: 
Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an 
international comparison. Diabet Med 2015;32:1036-1050 
16. Hofer SE, Schwandt A, Holl RW: Standardized Documentation in Pediatric Diabetology: 
Experience From Austria and Germany. J Diabetes Sci Technol 2016;10:1042-1049 
17. Warner J, Morris S: The National Paediatric Diabetes Audit. Practical Diabetes 
2014;31:257-261 
18. Beck RW, Tamborlane WV, Bergenstal RM, Miller KM, DuBose SN, Hall CA, Network 
TDEC: The T1D Exchange clinic registry. J Clin Endocrinol Metab 2012;97:4383-4389 
19. Svensson J, Cerqueira C, Kjaersgaard P, Lyngsoe L, Hertel NT, Madsen M, Mortensen 
HB, Johannesen J: Danish Registry of Childhood and Adolescent Diabetes. Clinical 
epidemiology 2016;8:679-683 
20. Margeirsdottir HD, Larsen JR, Kummernes SJ, Brunborg C, Dahl-Jorgensen K: The 
establishment of a new national network leads to quality improvement in childhood diabetes: 
implementation of the ISPAD Guidelines. Pediatr Diabetes 2010;11:88-95 
21. American Diabetes A, European Association for the Study of D, International Federation 
of Clinical C, Laboratory M, International Diabetes F: Consensus statement on the worldwide 
standardisation of the HbA1c measurement. Diabetologia 2007;50:2042-2043 
22. Patient Reported Outcome Measures (PROMs) in England: The case-mix adjustment  
methodology [article online], 2012. Available from 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/216507/dh_13
3449.pdf.  
23. Merlo J, Chaix B, Ohlsson H, Beckman A, Johnell K, Hjerpe P, Rastam L, Larsen K: A 
brief conceptual tutorial of multilevel analysis in social epidemiology: using measures of 
clustering in multilevel logistic regression to investigate contextual phenomena. Journal of 
epidemiology and community health 2006;60:290-297 
24. Samuelsson U, Akesson K, Peterson A, Hanas R, Hanberger L: Continued improvement of 
metabolic control in Swedish pediatric diabetes care. Pediatr Diabetes 2016; 
25. Fung CH, Lim YW, Mattke S, Damberg C, Shekelle PG: Systematic review: the evidence 
that publishing patient care performance data improves quality of care. Ann Intern Med 
2008;148:111-123 
26. Smith PC, Mossialos E, Papanicolas I, Leatherman S: Performance Measurement for 
Health System Improvement: Experiences, Challenges and Prospects. Cambridge University 
Press, 2010 
27. Girling I, Day E, Fazakerley K, Gray T, Hindmarsh P, Musgrove N, Rahman S, Trevelyan 
N, Warner J, Christie D, On behalf of the Royal College of Paediatrics Child Health the 
22 
 
National Paediatric Diabetes Audit Patient Reported Experience Measure working g: What 
young people want from their diabetes team: developing a patient reported experience measure 
(PREM) for young people with type 1 diabetes. Practical Diabetes 2015;32:142-147a 
28. Swift PG, Skinner TC, de Beaufort CE, Cameron FJ, Aman J, Aanstoot HJ, Castano L, 
Chiarelli F, Daneman D, Danne T, Dorchy H, Hoey H, Kaprio EA, Kaufman F, Kocova M, 
Mortensen HB, Njolstad PR, Phillip M, Robertson KJ, Schoenle EJ, Urakami T, Vanelli M, 
Ackermann RW, Skovlund SE, Hvidoere Study Group on Childhood D: Target setting in 
intensive insulin management is associated with metabolic control: the Hvidoere childhood 
diabetes study group centre differences study 2005. Pediatr Diabetes 2010;11:271-278 
29. Sherr JL, Hermann JM, Campbell F, Foster NC, Hofer SE, Allgrove J, Maahs DM, 
Kapellen TM, Holman N, Tamborlane WV, Holl RW, Beck RW, Warner JT, T1D Exchange 
Clinic Network tDPVI, the National Paediatric Diabetes A, the Royal College of P, Child 
Health r: Use of insulin pump therapy in children and adolescents with type 1 diabetes and its 
impact on metabolic control: comparison of results from three large, transatlantic paediatric 
registries. Diabetologia 2016;59:87-91 
30. Willi SM, Miller KM, DiMeglio LA, Klingensmith GJ, Simmons JH, Tamborlane WV, 
Nadeau KJ, Kittelsrud JM, Huckfeldt P, Beck RW, Lipman TH, Network TDEC: Racial-ethnic 






Table 1. Participant characteristics and data sources by country 
















* ISPAD target 
achievement, % Definition % mmol/mol % 




Patient born outside 
of Sweden 
13 59 (13) 7.6 (1.2) 49 




Patient or at least one 
parent born outside 
of Germany/Austria 
20 61 (15) 7.7 (1.4) 46 




Patient or at least one 
parent born outside 
of Germany/Austria 
28 62 (16) 7.8 (1.4) 43 




Both parents born 
outside of Denmark 
8 64 (16) 8.0 (1.5) 38 




Mother born outside 
of the Nordic 
countries 
6 66 (14) 8.2 (1.3) 29 






27 71 (18) 8.6 (1.6) 20 







22 72 (17) 8.7 (1.6) 18 






5 72 (18) 8.8 (1.6) 17 
* Data shown as mean (standard deviation). International Society of Pediatric and Adolescent Diabetes (ISPAD) HbA1c target of <58 mmol/mol (7.5%). 
DPV: Prospective Diabetes Follow-up Registry, DanDiabKids: Danish National Diabetes Registry, NPDA: National Paediatric Diabetes Audit, NCDR: Norwegian Childhood Diabetes 
Registry, SWEDIABKIDS: Swedish Pediatric Diabetes Quality Registry. HbA1c completeness defined as proportion of eligible children in each country having a recorded HbA1c 









Table 2. Absolute and relative measures of centre variation in HbA1c by country after adjustment for patient characteristics 
 
 
Sweden Germany Austria Denmark Norway England USA Wales 
HbA1c difference between centres in the 
highest and lowest decile - mmol/mol 
(%)* 
6.0 (0.6) 14.5 (1.3) 15.7 (1.4) 9.8 (0.9) 6.6 (0.6) 11.0 (1.1) 12.8 (1.2) 12.3 (1.1) 
Proportion of total variance in HbA1c 
attributable to differences between 
centres (Intra-Class Correlation) † 
4.0% 16.8% 13.9% 4.0% 1.8% 5.5% 7.9% 4.7% 
All analyses conducted separately in each country and were adjusted for patient characteristics with regard to individual gender, age, duration of 
diabetes and minority status.  
* fixed effect models 
† models with a random effect for centre 
